Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
COVID Situation Still Fluid
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.
You may also be interested in...
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
Even at $2.40 per test, tens of millions of tests provided add up quickly to deplete China’s medical insurance pool. Now the government wants localities to step and pay.